Pfizer is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023. It just might take a while before that bet pays off. The company is laying off hundreds of employees and shaving down its research and development spending.